ArticleThe Kaohsiung journal of medical sciences2026
Liposomal Bupivacaine Versus Ropivacaine in Combined Thoracic Paravertebral Block and Serratus Anterior Plane Block for Thoracoscopic Surgery: A Randomized Controlled Trial.
Article in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study aimed to compare the use of liposomal bupivacaine (LB) and ropivacaine hydrochloride (RH) in combined thoracic paravertebral block (TPVB) and serratus anterior plane block (SAPB) during video-assisted thoracoscopic surgery (VATS). The primary outcome was cumulative consumption of 72-h morphine milligram equivalent (MME) postoperatively. The secondary outcomes were MME consumption at 0-24 h, 24-48 h, and 48-72 h postoperatively, scores of visual analogue scale (VAS) at 6, 12, 24, 48, and 72 h postoperatively, effective times of patient-controlled intravenous analgesia (PCIA), and first time to request for analgesia. The LB-TPVB-SAPB group (n = 66) exhibited a decrease in total MME consumption within 72 h postoperatively compared to the RH-TPVB-SAPB group (n = 66) [independent t-test: p < 0.0001, Cohen's d = -1.05; mean difference with 95% confidence interval: -14.02 (-18.68 to -9.35)]. Bonferroni multiple comparisons test after repeated-measures ANOVA showed less MME consumption at 0-24 h (p < 0.001) and 24-48 h (p = 0.013) with lower VAS scores at 24 (p < 0.001) and 48 h (p = 0.002) postoperatively in the LB-TPVB-SAPB group than the RH-TPVB-SAPB group. Fewer effective times of PCIA and longer time to first request for analgesia were also observed in the LB-TPVB-SAPB group than the RH-TPVB-SAPB group. In conclusion, this study demonstrates LB in combined TPVB and SAPB could reduce postoperative opioid consumption compared to RH in this combination after VATS and the absolute change in postoperative opioid consumption exceeds the reported minimal clinically important difference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.